Emma Andrus, Editor

Upadacitinib shows promising results in treating severe alopecia areata, achieving significant hair regrowth and setting new efficacy standards in therapy.

In part 3 of this Case-Based Roundtable supplement, Seemal Desai, MD, FAAD; Ted Lain, MD, MBA, FAAD; and Pearl Grimes, MD, FAAD, discuss real-world vitiligo scenarios, offering diagnostic insights, therapeutic strategies, and practical pearls from their own experiences.

In part 2 of this Case-Based Roundtable supplement, Seemal Desai, MD, FAAD; Ted Lain, MD, MBA, FAAD; and Pearl Grimes, MD, FAAD, discuss real-world vitiligo scenarios, offering diagnostic insights, therapeutic strategies, and practical pearls from their own experiences.

In part 1 of this Case-Based Roundtable supplement, Seemal Desai, MD, FAAD; Ted Lain, MD, MBA, FAAD; and Pearl Grimes, MD, FAAD, discuss real-world vitiligo scenarios, offering diagnostic insights, therapeutic strategies, and practical pearls from their own experiences.

From remote villages to island nations, a WHA resolution and grassroots efforts aim to bridge care gaps in regions lacking access to dermatology providers.

Clinicians at the SDPA Annual Summer Dermatology Conference explore innovative treatments, diagnostic strategies, and patient-centered care in dermatology.

Ted Lain, MD, MBA, moderated a Case-Based Roundtable event to discuss diverse case presentations of vitiligo and how to build a treatment regimen.

Discover how the NEA Seal of Acceptance helps clinicians recommend safe eczema products, ensuring quality and sensitivity for patients with atopic dermatitis.

Explore personalized systemic therapies for atopic dermatitis, addressing patient needs, treatment options, and enhancing adherence for better outcomes.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Michael Somenek, MD, shares how a first-of-its-kind Galderma trial using Sculptra and Restylane helped restore volume and skin quality in patients on GLP-1 medications.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Renata Block, DMSc, MMS, PA-C, interviews Adam Friedman, MD, FAAD, about his research into cannabidiol’s photoprotective potential, clinical trial design, and future directions.

O'Dowd discusses J&J's recent NDA submission for icotrokinra in psoriasis.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

AbbVie's upadacitinib showed promising results in treating severe alopecia areata, achieving significant hair regrowth in pivotal phase 3 trials.

Delgocitinib cream recently became the first FDA-approved treatment for chronic hand eczema. Robert Spurr of LEO Pharma shares insights into what it means for providers and patients.

This review of the latest dermatologic studies includes insights into emerging terbinafine resistant trichophyton dermatophytosis, clinicodemographic features and usage of oral immunosuppressive agents in childhood and adolescent vitiligo, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Nektar Therapeutics advances alopecia areata treatment with FDA's Fast Track designation for rezpegaldesleukin, targeting immune modulation in chronic hair loss.

Dermatology Times is looking back on the top stories in dermatology from the month of July.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Dermatology Times is recapping our exclusive expert interviews from the month of July.

Learn more about the in-depth topics covered in the July 2025 print issue of Dermatology Times.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

The approval makes delgocitinib cream the first and only approved therapy in the US for CHE in adults.

Castle Biosciences’ DecisionDx-Melanoma test plays a role in melanoma management with precise risk stratification, enhancing patient outcomes and reducing unnecessary surgeries.

Tildrakizumab, HCP-administered biologics, and lifestyle-based decision-making took center stage in an interactive discussion led by Omar Noor, MD, FAAD, and colleagues.

This review of the latest dermatologic studies includes insights into pruritus as an indicator for QoL in CTCL, the research landscape of acquired dermal macular hyperpigmentation, and more.